Acromegaly and Growth Hormone Pharmacotherapy

Acromegaly: treatment goals and baseline assessment

In most patients with a resectable GH-secreting pituitary adenoma, transsphenoidal surgery is the preferred initial treatment. Persistently elevated IGF-I after surgery, residual tumor, or inability to undergo surgery may prompt medication. Evaluate IGF-I using age-adjusted ranges, GH suppression as appropriate, tumor size and mass effects, visual symptoms, glucose intolerance, sleep apnea, cardiovascular complications, arthropathy, and other pituitary deficiencies.

Baseline decision-making after pituitary surgery

Compare postoperative IGF-I (using age-appropriate reference ranges), GH suppression when appropriate, residual lesion size, visual symptoms, pituitary deficits, and comorbid disease. Persistent biochemical activity after surgery is a treatment indication even if acral changes are no longer progressing. Evaluate diabetes, hypertension, sleep apnea, cardiomyopathy, arthropathy, colon neoplasia risk, and hypopituitarism. A treatment goal is both biochemical control and reduction of future morbidity; improvement in appearance may lag behind hormone changes (Polomoff et al., 2026).

Somatostatin receptor ligands

Octreotide and lanreotide act at somatostatin receptors to suppress GH secretion and may also reduce tumor size. Long-acting injections are common treatment options; oral delayed-release octreotide may be considered in selected patients already responding to and tolerating injectable somatostatin analog treatment. Selection accounts for biochemical severity, tumor burden, injection burden, access, and patient preference (Polomoff et al., 2026).

For octreotide and lanreotide, assess glycemia, thyroid function, gastrointestinal effects, and clinically significant bradycardia or conduction symptoms. Gallstones and other biliary complications may result from reduced gallbladder emptying; assess symptoms and apply the monitoring plan in the specific product label. Pasireotide has a greater risk of clinically important hyperglycemia, sometimes with ketoacidosis. For Signifor LAR, assess fasting glucose or A1c, liver function, ECG, and potassium and magnesium before treatment; optimize poorly controlled diabetes, then continue glucose and drug-specific safety surveillance during initiation, titration, and withdrawal. Signifor LAR is a clinician-administered intramuscular product with separate acromegaly and Cushing disease dosing and is not interchangeable with subcutaneous Signifor (Ipsen Biopharmaceuticals, Inc., 2024; Polomoff et al., 2026; Recordati Rare Diseases Inc., 2024).

Choose formulation by efficacy, practicality, and glycemic risk

Long-acting octreotide and lanreotide are common options when surgery is incomplete or unsuitable. Their injection schedules, administration requirements, and follow-up differ from oral octreotide. Signifor LAR (pasireotide) is a distinct, clinician-administered intramuscular formulation: the U.S. label starts acromegaly treatment at 40 mg every four weeks, versus 10 mg every four weeks for Cushing disease. For moderate hepatic impairment (Child-Pugh B) in acromegaly, the labeled starting dose is 20 mg every four weeks, with a 40-mg maximum; avoid use in Child-Pugh C. Evaluate glucose or A1c, ECG, potassium, magnesium, and liver function before use. The risks of hyperglycemia and ketoacidosis make untreated or poorly controlled diabetes an important prescribing concern (Polomoff et al., 2026; Recordati Rare Diseases Inc., 2024).

Assess response beyond a single IGF-I concentration

Track IGF-I at a drug-appropriate interval after initiation or dose change, clinical symptoms, glucose, thyroid function, and tumor imaging according to anatomy and disease course. An apparently adequate IGF-I decrease does not exclude progressive headache, visual change, or other mass effects. Conversely, symptoms may persist from irreversible arthropathy despite biochemical control, and increasing hormone suppression in that circumstance may add toxicity without benefit.

Route and formulation are treatment decisions, not mere preferences

Long-acting octreotide and lanreotide provide sustained somatostatin-receptor activity but differ in administration route, interval, access, and tolerability. Delayed-release oral octreotide is a potential option for selected patients who have already demonstrated response and tolerance to injectable octreotide or lanreotide. It should not be presented as an equivalent substitute for every patient with uncontrolled acromegaly (Polomoff et al., 2026).

When considering a change of formulation, document the most recent IGF-I response, residual tumor status, injection burden, practical administration requirements, adverse effects, and the plan for repeat clinical and biochemical assessment. A medication switch that reduces injection burden but worsens biochemical control may require reversal or another strategy. Pegvisomant also requires monitoring for liver injury and tumor behavior, because normalizing IGF-I does not demonstrate tumor shrinkage.

GH-receptor blockade and dopamine agonists

Pegvisomant blocks peripheral growth-hormone receptor signaling and is evaluated principally through age-adjusted IGF-I and the clinical response; circulating GH is not an appropriate marker of drug effect. Because it does not directly suppress pituitary tumor growth, reassess residual tumor behavior with imaging when indicated. Assess transaminases, total bilirubin, and alkaline phosphatase before treatment and periodically thereafter, with prompt evaluation of symptoms suggesting liver injury (Polomoff et al., 2026).

For pegvisomant (Somavert), the current label directs baseline liver testing. With normal baseline results, repeat monthly for six months, every three months for the next six months, then every six months for the following year. Baseline results at most three times ULN require more intensive monitoring, and results above three times ULN require evaluation before initiating therapy. During treatment, AST/ALT at least three but below five times ULN without symptoms or bilirubin rise prompts close weekly monitoring and workup; at least five times ULN or at least three times ULN with bilirubin elevation requires discontinuation. Dose titration follows age-adjusted IGF-I, not GH; structural tumor assessment requires separate MRI surveillance (Pharmacia & Upjohn Company LLC, 2023).

Cabergoline can be considered as adjunctive therapy for modest IGF-I elevation in selected patients with acromegaly, but is less effective than somatostatin analogs or GH receptor blockade for most patients. This use differs from the hyperprolactinemia indication in the June 2026 U.S. cabergoline label, which calls for pretreatment echocardiography and surveillance every 6–12 months or as clinically indicated. The 2023 Pituitary Society prolactinoma consensus proposes longer dose-adapted surveillance intervals. Because those recommendations differ and the consensus concerns prolactinoma, follow the exact dispensed product labeling and an individualized endocrinology/cardiology plan rather than transferring one schedule automatically to acromegaly (Mylan Pharmaceuticals Inc., 2026; Petersenn et al., 2023).

Acromegaly pharmacotherapy comparison

Class-specific response determines the next intervention

Drug selection must distinguish biochemical control from control of the residual tumor. Somatostatin receptor ligands may lower GH secretion and reduce tumor size in selected patients; pegvisomant can normalize IGF-I without directly reducing tumor growth. After changing treatment, specify both an IGF-I reassessment plan and a separate imaging strategy, as well as adverse-effect surveillance tailored to the chosen class (Polomoff et al., 2026).

Drug class	Therapeutic action	Clinical limitation
Octreotide / lanreotide	Suppress GH and may shrink adenoma	GI effects, biliary effects, glucose and thyroid changes
Pasireotide	Suppress GH in selected refractory disease	Higher hyperglycemia risk
Pegvisomant	Block peripheral GH receptor; lower IGF-I	Liver monitoring; tumor surveillance required
Cabergoline	Dopamine agonism; modest GH suppression	Less potent; dizziness/orthostasis
Recombinant growth hormone for confirmed GH deficiency	Replace GH activity; titrate by age-adjusted IGF-I, clinical response and adverse effects	Distinct therapeutic objective from acromegaly suppression; assess glucose, edema, joint symptoms and other pituitary replacements.

GH deficiency: confirm indication before replacement

Short stature is not synonymous with GH deficiency. In children, exclude malnutrition, chronic disease, hypothyroidism, genetic disorders, and other causes before interpreting GH stimulation testing. In adults, confirm pituitary disease and assess other hormone deficits. Do not assume that fatigue alone establishes eligibility for somatropin. Active malignant disease and other serious contraindications require review before treatment.

Address untreated pituitary deficits before GH replacement

A patient with pituitary disease may have concomitant ACTH deficiency, central hypothyroidism, or gonadotropin deficiency. Treat unstable adrenal insufficiency before GH initiation and assess thyroid status because starting GH can reveal or worsen central hormone deficiency. Confirm the diagnosis with the testing strategy appropriate to pediatric or adult disease. GH is not indicated simply to treat nonspecific fatigue, aging, or weight concerns (Polomoff et al., 2026).

GH replacement and titration

Recombinant GH (somatropin) is administered subcutaneously, while selected long-acting formulations allow less frequent injections. Weekly products differ in their approved ages, indications, dosing systems, and administration instructions; verify the specific product before prescribing or switching. Selection should account for dosing schedule, device technique, cost, adherence, and risk of treatment-related hyperglycemia. Daily and weekly products are not dose-for-dose interchangeable (Polomoff et al., 2026).

Pediatric treatment is weight-based and guided by growth velocity and pubertal development; reported regimens include approximately 22–35 micrograms/kg/day as a starting range for prepubertal children, individualized with growth response. Pediatric and adult dosing are not interchangeable. Because dose needs vary by estrogen exposure, age, and other pituitary hormone deficiencies, consultation with an endocrinology team is central to safe selection and adjustment.

Age and metabolic status change adult GH initiation

For confirmed adult GH deficiency, illustrative daily starting ranges include approximately 0.4–0.5 mg for adults younger than 30, 0.2–0.3 mg at 30–60 years, and 0.1–0.2 mg above 60 years. Lower initial doses around 0.1–0.2 mg/day may be appropriate with diabetes, obesity, or metabolic risk. Typical cautious increments of 0.1–0.2 mg/day are considered at approximately one- to two-month intervals, guided by age-adjusted IGF-I, edema, arthralgia, paresthesias, glucose, and clinical response. These are educational source ranges, not universal or interchangeable product orders (Polomoff et al., 2026).

The same approach must not be imposed on a child with growth failure. Pediatric treatment is individualized using weight-related dosing, height velocity, skeletal maturation, puberty, and IGF-I. Growth hormone also can unmask or change requirements for other pituitary hormone replacement, so review adrenal and thyroid status before initiation and during titration.

Monitoring and adverse effects of GH treatment

Growth hormone response: titration is constrained by tolerability

In adult growth hormone deficiency, dose selection and follow-up differ from pediatric height-based treatment. Initial adult dosing is stratified by age and comorbidity, with lower initial doses for older adults, diabetes, or obesity, and cautious titration guided by IGF-I, symptoms, and adverse effects. Arthralgia, edema, paresthesia, or worsening glycemic control should prompt reassessment rather than automatic dose escalation to achieve a numerical IGF-I target.

Patients with multiple pituitary deficiencies require coordinated hormone management. GH replacement may change the apparent adequacy of thyroid and adrenal replacement; review free T4, symptoms suggesting cortisol deficiency, and other pituitary axes during initiation and dose changes. If hypothalamic-pituitary disease is associated with residual mass, align biochemical surveillance with the established MRI plan.

In children, monitor height, height velocity, IGF-I, thyroid function, and growth response at age-appropriate intervals. In adults, assess IGF-I, edema, arthralgia, carpal tunnel symptoms, glucose status, sleep apnea or cardiometabolic risk, and quality-of-life response. GH can unmask central hypothyroidism or alter glucocorticoid requirements; review existing thyroid and adrenal replacement as GH treatment is introduced.

Prevent endocrine and metabolic complications

Monitor edema, arthralgia, carpal tunnel symptoms, glucose intolerance, excessive IGF-I, and symptoms of intracranial hypertension during somatropin therapy. In children, a new limp, hip or knee pain, or scoliosis progression requires clinical assessment. Somatropin can expose previously unrecognized central hypothyroidism or increase glucocorticoid replacement requirements in patients with hypoadrenalism; review thyroid and adrenal status after initiation or escalation rather than assuming prior doses remain adequate (Pfizer Inc., 2026; Polomoff et al., 2026).

Do not confuse biochemical response with tumor control

A patient on pegvisomant has normalized IGF-I but reports worsening headache and new peripheral vision loss. IGF-I indicates peripheral GH receptor blockade, not the size or behavior of a residual pituitary adenoma. Arrange prompt pituitary imaging and specialist review; escalating pegvisomant on symptoms alone or interpreting normal IGF-I as reassuring about mass effect would be inappropriate (Polomoff et al., 2026).

Applied clinical decision-making

In an adult with persistent IGF-I elevation after pituitary surgery, poorly controlled diabetes, and reduced hepatic reserve, the treatment tradeoff requires explicit comparison. Pasireotide may further impair glycemic control; pegvisomant may improve glycemic measures but requires liver-test surveillance and continued imaging because lowering IGF-I does not directly suppress tumor growth. Somatostatin analogs may address secretion and tumor size, depending on response. Endocrinology should individualize the choice using IGF-I, tumor anatomy, liver status, diabetes control, and treatment feasibility (Pharmacia & Upjohn Company LLC, 2023; Polomoff et al., 2026).

An older adult with confirmed GH deficiency and diabetes develops edema and arthralgia after a somatropin dose increase. Do not continue escalating therapy solely to place IGF-I near the midpoint of the age-adjusted reference interval. Reassess treatment benefit, adverse effects, glycemic control, and need for dose reduction; older patients may be particularly susceptible to dose-related fluid retention and musculoskeletal symptoms (Polomoff et al., 2026).

Case: Growth hormone deficiency with untreated adrenal insufficiency

An adult with confirmed GH deficiency and untreated central adrenal insufficiency requests immediate somatropin. Before GH initiation, stabilize the other pituitary deficiencies and reassess the replacement plan; GH can change glucocorticoid and thyroid hormone requirements. Start an age-appropriate low dose only with endocrinology-directed IGF-I and metabolic monitoring. Treating an isolated IGF-I value without confirming the endocrine diagnosis creates avoidable risk (Polomoff et al., 2026).

Growth hormone therapy: what the patient monitors

Teach the patient to report persistent edema, joint pain, paresthesias, worsening glucose control, headache, or concerning visual symptoms during growth hormone replacement. In acromegaly, explain why biochemical control and tumor surveillance are separate outcomes: pegvisomant may normalize IGF-I without directly controlling tumor growth, while somatostatin analogs have distinct gastrointestinal, gallbladder, and glycemic effects. Confirm the formulation-specific injection schedule, missed-dose instructions, and who is responsible for IGF-I measurements, hepatic monitoring where indicated, and follow-up pituitary imaging (Polomoff et al., 2026).

High-yield distinctions

IGF-I is the primary biochemical response marker for GH-receptor blockade. Somatostatin analogs suppress GH secretion and may reduce tumor size, whereas pegvisomant does not provide primary tumor shrinkage. Acromegaly treatment and GH replacement have opposite treatment goals, and using doses or monitoring logic from one for the other is unsafe.

Related YourDNP Resources

Pharmacology hub · Endocrine pathophysiology foundations · Hyperprolactinemia pharmacotherapy · Hypothyroidism pharmacotherapy · Adrenal insufficiency pharmacotherapy

---

---

References

Ipsen Biopharmaceuticals, Inc. (2024). Somatuline Depot (lanreotide acetate) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e4a41fd-a753-4362-87ee-8cc56ed3660d

Mylan Pharmaceuticals Inc. (2026). Cabergoline tablets [Prescribing information; revised June 2026]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e497366b-a124-4d7f-bd45-a883c392d4bb

Petersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M. K., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., Greenman, Y., Gurnell, M., Ho, K. K. Y., Honegger, J., Ioachimescu, A. G., Kaiser, U. B., Karavitaki, N., Katznelson, L., Lodish, M., … Melmed, S. (2023). Diagnosis and management of prolactin-secreting pituitary adenomas: A Pituitary Society international consensus statement. Nature Reviews Endocrinology, 19, 722–740. https://doi.org/10.1038/s41574-023-00886-5

Pfizer Inc. (2026). Genotropin (somatropin) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765

Pharmacia & Upjohn Company LLC. (2023). Somavert (pegvisomant) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cbb485b-6df1-49ce-8747-592b395b1988

Polomoff, C. M., Dang, D. K., & Chen, J. T. (2026). Pituitary gland disorders. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 1490–1529). McGraw Hill.

Recordati Rare Diseases Inc. (2024). Signifor LAR (pasireotide) [Prescribing information; revised July 2024]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0aad470-3f38-af97-e053-2995a90a383a